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Introduction {#sec005}
============

Testing for high-risk human papillomavirus (hrHPV), cause of virtually all cervical cancer, is increasingly the preferred method for screening to prevent cervical cancer in mid-adult women living in high-income countries (HIC) and low- and middle-income countries (LMICS) \[[@pone.0229086.ref001]--[@pone.0229086.ref003]\]. One of the important advantages of hrHPV testing-based screening over cytology-based screening is that the former empowers women by allowing them to self-collect their own cervicovaginal specimen rather than needing to have a pelvic exam to get a provider-collected specimen and permits them to collect their own specimen in privacy, as well as elsewhere than at the clinic. Importantly, there is strong evidence that the use of self-collected cervicovaginal specimen with hrHPV testing is as accurate as using a provider-collected cervical specimen, increases participation in screening, and self-collection at home is preferred over clinic-based screening \[[@pone.0229086.ref004]--[@pone.0229086.ref007]\].

To examine the feasibility of introducing HPV testing of self-collected vaginal samples and a hrHPV screen-and-treat algorithm in Botswana, a high HIV and cervical-cancer burden country where cervical cancer is the leading cause of cancer-related deaths among women \[[@pone.0229086.ref008]\], we conducted a pilot study among women attending five public health facilities (one district hospital and four health clinics and surrounding communities) in the Kweneng East District in Botswana in a convenience sample of approximately 1,000 women, enriched for women living with HIV (WLWH). Women who were seeking sexual and reproductive health (SRH) services were asked to self-collect their specimen, which was tested for hrHPV, and hrHPV-positive women underwent visual assessment and treatment according to World Health Organization (WHO) recommendations \[[@pone.0229086.ref001];[@pone.0229086.ref009]\]. Here, we report the hrHPV testing results, using a WHO prequalified hrHPV test \[[@pone.0229086.ref010]\], in relationship to basic demographic data and HIV status (positive vs. negative) as well as what treatment these women underwent.

Methods {#sec006}
=======

Study ethics approval {#sec007}
---------------------

Before commencing the study, the Johns Hopkins School of Public Health (JHSPH) Institutional Review Board approved the study (reference IRB00007974).

A convenience sample of 1,022 women aged 30--49 years living in Kweneng East District in Botswana, which serves approximately 46,000 women in this age group, was recruited to participate in a pilot demonstration project on self-collection-based HPV screening. Women were recruited in equal (20%) proportions, between 203--206 participants from five health facilities, designated as A, B, C, D, and E, to insure anonymity. Dates for recruitment were October 2017 --March 2018. All five health facilities conducted recruitment at their respective facilities, while two health facilities (B and E) also conducted recruitment in the community during health outreach activities. In these two facilities, recruitment was planned to be half and half from the health facility and in the community each serves through existing integrated community health outreaches, but 70% were recruited from the community health outreach for one facility (B). Women at the clinics were recruited after coming to the facility for cervical cancer screening following contact with a research nurse and from various health service points at the clinic, such as family planning, outpatient, and HIV care. Women attending the latter were specifically targeted to enrich the study sample for WLHW.

Eligible women were recruited by the research nurses who conducted group education on HPV and cervical cancer, the ways to prevent it, and described the study. Eligible and interested women then met individually with the research nurse to confirm eligibility and interest. Eligible women who remained interested in participating in the study were then consented and enrolled. The research nurses obtained written informed consent of the study participants by providing a written copy of the consent form, in Setswana, to the participant and reading the form to them, confirming understanding of all aspects of the study, including volunteer participation. The research nurse then printed the client's name and obtained her signature and date of the informed consent. Consented women were then instructed on how to self-collect their specimen. For community recruitment, the study used the existing community health campaign mechanism to integrate cervical cancer screening using HPV self-collection into these community outreach events.

Inclusion/exclusion criteria were: 1) aged 30 to 49 years; 2) not screened recently/never screened before, defined as self-report of no prior history of cervical cancer screening, prior screening but result unknown and no treatment, or screening occurred more than 5 years ago for HIV negative women or 3 years ago for WLHW; 3) HIV status known (HIV positive result, or documented HIV negative result is less than 12 months ago); 4) no history of prior abnormal screening or treatment/procedure on her cervix due to abnormal screening; 5) no history of cervical cancer; 6) not currently pregnant and not less than 6 weeks postpartum; 7) an intact uterus/no prior hysterectomy with complete removal of the cervix; 8) accesses health services in Kweneng East District study catchment area; and 9) able and willing to provide consent.

The research nurse collected basic demographic and contact information, including telephone number(s) to allow for follow up with results. The Senior Research Nurse then distributed HPV self-collection kits which included a sampling brush (using Viba-Brush® (Rovers Medical Devices BV, Oss, the Netherlands) and a PreservCyt solution vial (Hologic, Bedford, MA, USA) to the woman, and she was instructed on proper self-collection technique. The woman then went to a designated private area to self-collect the cervicovaginal specimen, rinsed the collection device in the PreservCyt vial to elute the cells, capped the vial, and returned the vial to a research nurse.

The self-collected specimens were tested using the Xpert HPV Test, a qualitative, real-time PCR assay for the detection of hrHPV DNA per the manufacturer's instructions \[[@pone.0229086.ref010]\]. The Xpert HPV assay includes simultaneous detection of 14 hrHPV types, hydroxymethylbilane synthase (HMBS) and an internal Probe Check Control. The 14 targeted hrHPV genotypes (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) are detected in five fluorescent channels: 1) HPV16, 2) HPV18 and 45 (HPV18/45), 3) HPV31, 33, 35, 52, and 58 (HPV31/33/35/52/58), 4) HPV51 and HPV59 (HPV51/59), and 5) HPV39, 56, 66, and 68 (HPV39/56/66/68).

Women who tested hrHPV positive were asked to undergo further evaluation with a pelvic exam, at which time dilute acetic acid was placed on the cervix to perform visual assessment for treatment (VAT), i.e., to evaluate any cervical abnormalities that became white after dilute acetic acid was applied to the cervix ("acetowhite"), and decide the recommended treatment according to WHO guidelines \[[@pone.0229086.ref009];[@pone.0229086.ref011]\]. Nurses, midwives, and doctors, previously trained in visual inspection with acetic acid (VIA) and cryotherapy, performed VAT and triaged every HPV-positive client to determine treatment method. Abnormalities that covered less than three-quarters of the cervix, were completely visible i.e., did not go into the endocervical canal, and were not suspicious of cancer were deemed eligible for ablation and treated by cryotherapy. Those that covered three-quarters or more of the cervix and/or went into the endocervical canal were deemed ablation ineligible and were referred for loop electrosurgical excision procedure (LEEP). Those with suspected cancer were referred to colposcopy and biopsy and based on those results were then referred for care.

### Analysis {#sec008}

Age was categorized as 30--34, 35--39, 40--44, and 45--50 years. Crude and age group-adjusted prevalence, with 95% confidence intervals (95%CI) of any hrHPV and the individual hrHPV groups defined by the Xpert HPV Test channels, were calculated. Differences in crude and age group-adjusted prevalence between WLWH and HIV-negative women were tested for statistical significance (p\<0.05) using Fisher's exact and Wald chi-square tests, respectively. Unadjusted (crude) odds ratios (OR) and age group-adjusted ORs (aOR), with 95%CI, were calculated using logistic regression as a measure of the association of HIV status with hrHPV prevalence.

Differences in age between WLWH and HIV-negative women were tested for statistical significance using the Kruskal-Wallis Test. A linear regression model was used to predict the age-specific hrHPV for WLWH and HIV.

Crude and age group-adjusted hrHPV prevalence was compared across clinical sites and tested for differences using a Pearson chi-square and Wald chi-square tests, respectively. Differences in hrHPV prevalence between WLWH and HIV-negative women for a given site, or between community vs. facility recruitment by site and HIV status, were tested for statistical significance using a Fisher's exact test. Logistic regression models were used to calculate OR and 95%CI as a measure of association of age group, facility, and HIV status with hrHPV prevalence.

The outcome of VAT (no visible abnormality, visible abnormality and cryotherapy eligible, visible abnormality and cryotherapy ineligible, or suspected cancer) and hrHPV results, categorized hierarchically according to their cancer risk (HPV16 positive, versus HPV16 negative and positive for HPV18/45, versus HPV16 and 18/45 negative and positive for other hrHPV types), were compared. VAT outcomes and hrHPV risk group were tested for statistical significance using a test for trend \[[@pone.0229086.ref012]\].

Results {#sec009}
=======

The study recruited 1022 eligible women, 571 WLWH and 451 HIV-negative women; 1019 women had hrHPV results, 570 WLWH and 449 HIV-negative women. Although the age eligibility for the study was restricted to 30--49 years, the HIV-negative women (mean = 37.5, median = 36, and IQR = 33--42 years) enrolled in the study were significantly younger than the WLWH (mean = 39.4, median = 39, and IQR = 35--43 years) (p\<0.001).

Crude hrHPV prevalences were 25.2% (95%CI = 21.2--29.4%) for HIV-negative women and 40.4% (95%CI = 36.3--44.5%) for WLWH (**[Table 1](#pone.0229086.t001){ref-type="table"}**). hrHPV prevalence decreased with increasing age for both HIV-negative women and WLWH (p\<0.001 for both) (**[Fig 1](#pone.0229086.g001){ref-type="fig"}**). Because of the difference in age between the WLWH and HIV-negative women and the relationship of age with hrHPV prevalence, we also adjusted the hrHPV prevalence estimates for age. Age group-adjusted hrHPV prevalences were 23.7% (95%CI = 19.9--27.9%) for HIV-negative women and 41.3% (95%CI = 37.2--45.4%) for WLWH. The age group-adjusted OR for the association of being WLWH (vs. HIV-negative women) with hrHPV detection was 2.3 (95%CI = 1.7--3.0).

![Prediction of high-risk human papillomavirus (HPV) prevalence, stratified by HIV status, by age.\
Abbreviation: HIV, human immunodeficiency virus; WLWH, women living with HIV.](pone.0229086.g001){#pone.0229086.g001}

10.1371/journal.pone.0229086.t001

###### Prevalence of high-risk human papillomavirus (hrHPV) overall and individual hrHPV groups, as detected by the Xpert HPV Test, for human immunodeficiency virus (HIV)-negative women (n = 449) and women living with HIV (WLWH) (n = 570).
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HPV Test Result                                                      HIV-Negative Women   WLWH                                                                                               
  -------------------------------------------------------------------- -------------------- -------------- -------------- ----- -------------- -------------- --------- ------------ --------- ------------
  **Any hrHPV**[^**†**^](#t001fn003){ref-type="table-fn"}              113                  25.2\          23.7\          230   40.4\          41.3\          \<0.001   2.0\         \<0.001   2.3\
                                                                                            (21.2--29.4)   (19.9--27.9)         (36.3--44.5)   (37.2--45.4)             (1.5--2.6)             (1.7--3.0)

  **Channel 1**\                                                       14                   3.1\           2.8\           47    8.2\           8.3\           0.001     2.8\         \<0.001   3.2\
  **HPV16**                                                                                 (1.7--5.1)     (1.6--4.7)           (6.1--10.8)    (6.3--10.9)              (1.5--5.1)             (1.7--5.9)

  **Channel 2: HPV18/45**                                              18                   4.0\           3.7\           61    10.7\          10.9\          \<0.001   2.9\         \<0.001   3.1\
                                                                                            (2.4--6.4)     (2.3--5.9)           (8.3--13.5)    (8.5--13.7)              (1.7--4.9)             (1.8--5.4)

  **Channel 3:**\                                                      48                   10.7\          10.1\          121   21.2\          21.6\          \<0.001   2.3\         \<0.001   2.4\
  **HPV31/33/35/52/58**                                                                     (8.0--13.9)    (7.7--13.3)          (17.9--24.8)   (18.4--25.2)             (1.6--3.2)             (1.7--3.5)

  **Channel 4:**\                                                      23                   5.1\           5.0\           30    5.3\           5.3\           1         1.0\         0.811     1.1\
  **HPV51/59**                                                                              (3.3--7.6)     (3.3--7.5)           (3.6--7.4)     (3.7--7.5)               (0.6--1.8)             (0.6--1.9)

  **Channel 5:**\                                                      29                   6.5\           6.2\           62    10.9\          10.7\          0.02      1.7\         0.011     1.8\
  **HPV39/56/66/68**                                                                        (4.4--9.1)     (4.3--8.8)           (8.4--13.7)    (8.4--13.5)              (1.1--2.7)             (1.1--2.9)

  **Channel 1, 2, or 3**[^**†**^](#t001fn003){ref-type="table-fn"}:\   75                   16.7           15.6\          189   33.2\          33.9\          \<0.001   2.5\         \<0.001   2.8\
  **HPV16/18/31/33/35/45/52/58**                                                                           (12.5--19.2)         (29.3--37.2)   (30.0--37.9)             (1.8--3.5)             (2.0--3.8)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*crude hrHPV prevalence in WLWH vs. HIV-negative women

\*\*age-adjusted hrHPV prevalence in WLWH vs. HIV-negative women

^**†**^Because some women were positive for more than one of the channels, the number of positives does not equal the sum of the individual channels

Prevalences of most hrHPV groups, as determined by the Xpert HPV Test, also differed by HIV status (**[Table 1](#pone.0229086.t001){ref-type="table"}**). The age group-adjusted prevalence was lower for HIV-negative women than WLWH for HPV16 (2.8% vs. 8.3%, respectively, p\<0.001), HPV18/45 (3.7% vs. 10.9%, respectively, p\<0.001), HPV31/33/35/52/58 (10.1% vs. 21.6%, respectively, p\<0.001) and HPV39/56/66/68 (6.2 vs. 10.7%, respectively, p = 0.011). However, there was no significant difference in the age group-adjusted prevalence of HPV51/59 between HIV-negative women and WLWH (5.0 vs. 5.3%, respectively, p = 0.811). WLWH were twice as likely as HIV-negative women to be positive for multiple HPV groups (30% vs. 15.9%, respectively, p = 0.005).

We examined the hrHPV prevalence by clinical site (**[Table 2](#pone.0229086.t002){ref-type="table"}**). Age group-adjusted hrHPV prevalences varied significantly by clinical site among the HIV-negative women (range = 15.7% to 34.3%, p = 0.034). By comparison, the hrHPV prevalence was less variable by clinical site among WLWH (range = 34.1% to 46.4%, p = 0.196). Surprisingly, there were two health facilities, A and D, for which the hrHPV prevalence did not differ significantly by HIV status.

10.1371/journal.pone.0229086.t002

###### High-risk human papillomavirus (hrHPV) prevalence by health facility and human immunodeficiency virus (HIV) status.

Abbreviations: WLWH, women living with HIV.

![](pone.0229086.t002){#pone.0229086.t002g}

   Study Health Facility                    HIV-Negative Women   WLWH                                                         
  ----------------------------------------- -------------------- ------ ------- ------- ----- ----- ------- ------- --------- ---------
  A                                         84                   30     35.7    34.3    117   49    41.9    42.9    0.385     0.163
  B                                         92                   15     16.3    15.7    113   41    36.3    34.1    0.002     0.001
  C                                         72                   14     19.4    19.6    131   60    45.8    46.4    \<0.001   \<0.001
  D                                         93                   28     30.1    29.0    111   38    34.2    34.1    0.551     0.475
  E                                         108                  26     24.1    23.7    98    42    42.9    42.7    0.005     0.002
  Total                                     449                  113    25.2    23.7    570   230   40.4    41.3    \<0.001   \<0.001
  p[^†^](#t002fn003){ref-type="table-fn"}                               0.024   0.034               0.345   0.196             

\*difference in crude hrHPV prevalence in WLWH vs. HIV-negative women

\*\*difference in age-adjusted hrHPV prevalence in WLWH vs. HIV-negative women

^†^difference in hrHPV prevalence across facilities

Interestingly, the hrHPV prevalence differed between those recruited from the community or at the health facility for two (B and E) health facilities but only for HIV-negative women (**[Table 3](#pone.0229086.t003){ref-type="table"}**). At one health facility (B), the hrHPV prevalence was 30.4% in those recruited at the facility vs. 11.6% in those recruited from community (p = 0.050) among HIV-negative women. The hrHPV prevalence did not differ significantly between WLWH recruited at the facility or from community (35.1% vs. 36.8%, respectively, p = 1.000). In contrast, at another health facility (E), the hrHPV prevalence was 15.8% in those recruited at the facility vs. 33.3% in those recruited from community (p = 0.043) among HIV-negative women. Again, the hrHPV prevalence did not differ significantly between WLWH recruited at the facility or from community (39.1% vs. 46.2%, respectively, p = 0.543).

10.1371/journal.pone.0229086.t003

###### Prevalence of high-risk human papillomavirus (hrHPV) by HIV status (HIV-negative women or women living with HIV (WLWH)) and recruitment strategy (facility or community).
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  Study Health Facility   HIV-Negative   WLWH                                               
  ----------------------- -------------- ------ ---- ------ ------- ---- ------ ---- ------ -------
  B                       23             30.4   69   11.6   0.050   37   35.1   76   36.8   1.00
  E                       57             15.8   51   33.3   0.043   46   39.1   52   46.2   0.543

In a logistic regression model, HIV status, health facility, and age group were all independent predictors of hrHPV prevalence (**[Table 4](#pone.0229086.t004){ref-type="table"}**). Being HIV positive was strongly associated with having a hrHPV infection (aOR = 2.35, 95%CI = 1.76--3.14). Older women were less likely to have hrHPV infection than younger women, with women aged 45--49 years the least likely to have a hrHPV infection (aOR = 0.31, 95%CI = 0.20--0.49) compared to women aged 30--34 years.

10.1371/journal.pone.0229086.t004

###### Crude odds ratio (OR) and adjusted odds ratios (aOR), with 95% confidence intervals (95%CI), as measures of association of human immunodeficiency virus (HIV) status, health facility, and age-group with prevalent high-risk human papillomavirus (hrHPV) in women living in Botswana.
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  Variable            N (%)            OR             aOR (95%CI)             
  ------------------- ---------------- -------------- ----------------------- -----------------------
  HIV Status                                                                  
                      Negative (ref)   449 (44.06%)   1.0                     1.0
                      Positive         570 (55.94%)   **2.01 (1.53--2.64)**   **2.35 (1.76--3.14)**
  Facility                                                                    
                      A (ref)          201 (19.73%)   1.0                     1.0
                      B                205 (20.12%)   **0.58 (0.38--0.88)**   **0.53 (0.35--0.82)**
                      C                203 (19.92%)   0.89 (0.59--1.32)       0.84 (0.56--1.27)
                      D                204 (20.02%)   0.74 (0.49--1.11)       0.71 (0.47--1.08)
                      E                206 (20.22%    0.76 (0.51--1.14)       0.79 (0.52--1.20)
  Age Group (Years)                                                           
                      30--34 (ref)     271 (26.59%)   1.0                     1.0
                      35--39           305 (29.93%)   **0.63 (0.45--0.89)**   **0.50 (0.35--0.72)**
                      40--44           277 (27.18%)   0.79 (0.56--1.11)       **0.60 (0.42--0.86)**
                      45--49           166 (16.29%)   **0.42 (0.27--0.65)**   **0.31 (0.20--0.49)**

Finally, among hrHPV-positive women, the relationship of hierarchical hrHPV risk groups (HPV16\>HPV18/45\>other hrHPV types) and the visual status of the cervix (no visible lesion, visible abnormalities that was eligible for ablation, visible lesion that was ineligible for ablation, and suspected cancer) was examined (**[Table 5](#pone.0229086.t005){ref-type="table"}**). Riskier hrHPV groups were more likely to have visible abnormalities (42% for HPV16, 26% for HPV18/45, and 22% for other high-risk HPV; p~trend~ = 0.004) and visible abnormalities not eligible for cryotherapy (19% for HPV16, 12% for HPV18/45, and 8% for other high-risk HPV; p~trend~ = 0.030). Riskier hrHPV groups were more likely to have visible abnormalities (50% for HPV16, 18% for HPV18/45, and 17% for other high-risk HPV; p~trend~ = 0.013) among HIV-negative women (**[Table 6](#pone.0229086.t006){ref-type="table"}**). Riskier hrHPV groups were marginally more likely to have visible abnormalities among WLWH (40% for HPV16, 29% for HPV18/45, and 26% for other high-risk HPV; p~trend~ = 0.091) (**[Table 6](#pone.0229086.t006){ref-type="table"}**).

10.1371/journal.pone.0229086.t005

###### The relationship of high-risk human papillomavirus (hrHPV) and hrHPV risk groups and results of visual assessment for treatment.
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HPV Category                      Total   A. No Visible Abnormality:\   B. Visible Abnormality:\   C. Visible Abnormality:\                                   D. Cancer Suspected:\                                      Visible Lesions[\*\*](#t005fn002){ref-type="table-fn"}
                                            Ablation Eligible             Ablation Eligible          Ablation Ineligible[\*](#t005fn001){ref-type="table-fn"}   Ablation Ineligible[\*](#t005fn001){ref-type="table-fn"}   
  -------------------------- ------ ------- ----------------------------- -------------------------- ---------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------
  hrHPV Positive             N      328     240                           52                         32                                                         4                                                          88

  %Row                       100%   73%     16%                           10%                        1%                                                         27%                                                        

  HPV 16 Positive            N      61      34                            14                         10                                                         1                                                          25

  %Row                       100%   56%     23%                           16%                        2%                                                         42%                                                        

  HPV18/45 Positive;\        N      68      50                            10                         7                                                          1                                                          18
  HPV16 Negative                                                                                                                                                                                                           

  %Row                       100%   74%     15%                           10%                        1%                                                         26%                                                        

  Other hrHPV Positive;\     N      201     156                           28                         15                                                         2                                                          45
  HPV16 and 18/45 Negative                                                                                                                                                                                                 

  %Row                       100%   78%     14%                           7%                         1%                                                         22%                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*p~trend~ = 0.030 for HPV groups vs. ablation ineligible ((C + D)/Total)

\*\*p~trend~ = 0.004 for HPV groups vs. visible lesions ((B + C + D)/Total)

10.1371/journal.pone.0229086.t006

###### The relationship of high-risk human papillomavirus (hrHPV) and hrHPV risk groups and the presence of visible (acetowhite) cervical abnormalities, stratified on HIV status.
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  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
                             HIV-Negative Women[\*](#t006fn001){ref-type="table-fn"}   WLWH[\*\*](#t006fn002){ref-type="table-fn"}                          
  -------------------------- --------------------------------------------------------- --------------------------------------------- ----- ----- ---- ----- -------
  hrHPV Positive             109                                                       23                                            21%   219   65   30%   0.113

  HPV 16 Positive            14                                                        7                                             50%   45    18   40%   0.549

  HPV18/45 Positive;\        17                                                        3                                             18%   51    15   29%   0.527
  HPV16 Negative                                                                                                                                            

  Other hrHPV Positive;\     78                                                        13                                            17%   123   32   26%   0.164
  HPV16 and 18/45 Negative                                                                                                                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

\* p~trend~ = 0.013

\*\* p~trend~ = 0.091

^**†**^HIV-negative women vs. WLWH

Discussion {#sec010}
==========

In this pilot study of self-collection-based HPV screening of approximately one-thousand women living in Botswana, we made the following observations: 1) age-adjusted hrHPV prevalence was almost 2-fold higher in WLWH than HIV-negative women; notably, the hrHPV prevalence in HIV-negative women was high and quite variable between health facilities; 2) age, health facility, and HIV status were all predictors of prevalence hrHPV infection; and 3) riskier hrHPV groups were more likely to have visible cervical abnormalities and notably ablation-ineligible visible cervical abnormalities; approximately one-half and one-fifth of prevalent HPV16 had a visible cervical abnormality and ablation-eligible visible cervical abnormality, respectively.

There are few data published on the prevalence of cervical/cervicovaginal hrHPV in women living in Botswana. Luckett *et al*. \[[@pone.0229086.ref013]\] reported the hrHPV prevalence, as detected by Xpert on provider-collected cervical specimens, to be 29% in 300 WLWH with a median and interquartile range of age of 46 and 42--52 years, respectively. A sub-study (n = 103) in this same population of self-collection and hrHPV testing found 27% hrHPV prevalence in self-collected specimens \[[@pone.0229086.ref014]\]. Macleod *et al*. \[[@pone.0229086.ref015]\] reported the hrHPV prevalence, as detected by Linear Array (Roche, Pleasanton, CA, USA) on provider-collected cervical specimens, to be 25% in 139 WLWH with a median and interquartile range of age of 46 and 42--52 years, respectively. We found no published reports of the hrHPV prevalence in HIV-negative women.

The HPV prevalence in WLWH reported in this study was lower than observed in some populations \[[@pone.0229086.ref016]--[@pone.0229086.ref022]\], comparable to some populations \[[@pone.0229086.ref018];[@pone.0229086.ref023]--[@pone.0229086.ref026]\], and higher than in other populations \[[@pone.0229086.ref018];[@pone.0229086.ref027]\] living in SSA. We observed, as seen in other studies, that HIV status \[[@pone.0229086.ref024];[@pone.0229086.ref027]\] was an independent predictors of HPV prevalence in WLWH. However, the relative prevalence of hrHPV in WLWH vs. HIV-negative women, less than two-fold, was rather low compared to other studies that reported 2.5-fold or greater relative prevalence \[[@pone.0229086.ref020]--[@pone.0229086.ref022];[@pone.0229086.ref024];[@pone.0229086.ref028];[@pone.0229086.ref029]\]. This was in part due to the relatively high hrHPV prevalence in HIV-negative women, which was driven by high hrHPV prevalence (\>30%) in HIV-negative women recruited at certain health facilities. Age across sites was only marginally different (p = 0.055) and therefore probably does not explain the heterogeneity in hrHPV prevalence between them. Alternatively, higher-risk HIV-negative women were more likely to be recruited into and/or volunteer to participate in the study at some sites.

These data highlight the need for effective triage strategies for hrHPV-positive women, especially in WLWH populations, to increase the specificity and reduce the unnecessary treatment of benign hrHPV infections. Visual inspection after acetic acid (VIA) has been recommended as a triage of hrHPV \[[@pone.0229086.ref001]\] and would have cut down the number of women treated by \~73%. However, there are a number of limitations of using VIA as a triage test for an HPV-positive test including only moderate clinical performance, notably reduced sensitivity for high-grade cervical abnormalities \[[@pone.0229086.ref013];[@pone.0229086.ref030];[@pone.0229086.ref031]\]. A promising new strategy is the use of a deep learning-based automated visual evaluation tool that may provide real-time image analysis to identify sensitively and specifically those with high-grade cervical abnormalities and early cervical cancer \[[@pone.0229086.ref032]\].

HPV genotyping could also be used as the triage. Triage with HPV16, the HPV type responsible for 50--60% of cervical cancers \[[@pone.0229086.ref033]\], would reduce treatment by 82%. Triage with HPV16 and HPV18/45, HPV types responsible for \~75% of the cervical cancer \[[@pone.0229086.ref033]\], would reduce treatment by 62%. Alternatively, limiting the definition of a positive hrHPV test to the 8 hrHPV types (HPV16, HPV 18/45, and HPV31/33/35/52/58) that cause \~90% of cervical cancers \[[@pone.0229086.ref033]\] would reduce hrHPV positivity by approximately 34% in HIV-negative women and 18% in WLWH.

We found the HPV type, notably HPV16, was related to the appearance of the lesion. A study of women diagnosed with CIN2+ living in China found that the presence of HPV16 was associated with the presence of acetowhite lesions \[[@pone.0229086.ref034]\]. A study of unscreened women living Papua New Guinea found that HPV16 was also associated with VIA positivity \[[@pone.0229086.ref035]\]. In contrast, another study in The Netherlands and Spain did not find that any relationship of colposcopic appearance of a lesion \[[@pone.0229086.ref036]\]. We hypothesize that HPV16 infections cause the most obvious and severe appearing lesions, perhaps not surprisingly since HPV16 is the most carcinogenic HPV genotype \[[@pone.0229086.ref033];[@pone.0229086.ref037]\], and therefore the most likely abnormalities to be detected and treated in a well-screened population, like those of the Netherlands and Spain.

We acknowledge several limitations of our study. First, because this was a convenience sample of women, the true hrHPV prevalence in the whole population, as well as in WLWH and HIV-negative women cannot be truly estimated. The heterogeneity of hrHPV prevalence among the HIV-negative women by facility in fact may suggest non-representativeness of the sampling, or the samples of women from these locales/neighborhoods were indeed representative and there is significant variability in the population risk within the Kweneng East District catchment area.

Second, we did not have histologic endpoints or surrogates of cancer risk to consider potential tradeoffs in cervical cancer risk reduction vs. overtreatment by using different triage strategies. We can infer from a seminal international study on the attribution of cervical cancer to different HPV types \[[@pone.0229086.ref033]\] on what the impact of triaging hrHPV-positive women with HPV genotyping might be. We however cannot compare those tradeoffs to that of using VIA alone or in combination with HPV genotyping. Finally, we did not have data on CD4 cell counts for the WLWH, which would have allowed us to look at its impact on hrHPV prevalence. CD4 cell counts among WLWH has been shown to be an independent predictor of hrHPV prevalence\[[@pone.0229086.ref016];[@pone.0229086.ref023];[@pone.0229086.ref024]\].

Conclusions {#sec011}
===========

We present some of the first data on hrHPV prevalence in WLWH and HIV-negative women living in Botswana. As seen in other populations, we observed a significant overall difference in the hrHPV prevalence between WLWH and HIV-negative women. We also found that HPV16 was an important predictor of the appearance of an acetowhite lesion, a finding that should be verified in other studies.

We sincerely thank the women of Kweneng East District in Botswana who participated in this research, without whom we would have not been able to conduct this study. We thank the research nurses: Clever Manyenyengwa, Thebeyame Diswai, Letang Gaofiwe, Thabiso Doreen Moiketsi, Omphemetse Mmunyane, and Rebecca Ketlametswe. We also thank the nurses and doctors who helped evaluate and treat the women who tested HPV positive: Olga Mokgatle, Mokgabo Queen Nonyane, Lesego Chigagane, Dr. Maduke Kula, Dr. Monica Malunga, Dr. Thinambo Mondali, and Dr. Rebecca Luckett. We further thank the following for their contributions to the design, implementation and data analysis of the study: Eva Bazant, Jennifer Snyder, Rosinah Dialwa, Tracey Shissler, Megan Wysong, Tebogo Kenosi, and Tlhomamo Pheto.

10.1371/journal.pone.0229086.r001

Decision Letter 0

Chuang

Linus

Academic Editor

© 2020 Linus Chuang

2020

Linus Chuang

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

21 Jan 2020

PONE-D-19-35746

High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana

PLOS ONE

Dear Dr Varallo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Mar 06 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Linus Chuang

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified (1) whether consent was informed and (2) what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information.

3\. Thank you for including your ethics statement:  \"Johns Hopkins School of Public Health (JHSPH) Institutional Review Board IRB00007974\".   

Please amend your current ethics statement to confirm that your named institutional review board or ethics committee specifically approved this study.

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

4.  Thank you for stating the following in the Competing Interests section:

Philip E. Castle has received discounted or free HPV tests and assays for research purposes from Roche, Bectin Dickinson, Cepheid, and Arbor Vita Corporation. Otherwise, we have no conflicts of interest to disclose.

Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>).  If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

5\. We note that you have included the phrase "data not shown" in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This research article on hrHPV prevalence among HIV negative and WLWH in Botswana based on self-collected sample is a pilot demonstration study that documents success of self-collection in the Botswana context and provides new and insightful data on association of hrHPV and HIV. This is an impactful study and significant to the field of HIV/HPV and advances science on the use of HPV based screening in limited resource setting both among HIV negative and WLWH.

1\. Methods (population)- Recruitment at various facility based on site (health facility vs. community) is difficult to follow based on text presented. It is unclear if two of the recruitment sites only had community health based outreach recruitment?

2\. Result (Table 4)- Data as presented in the text does not match table 4. Furthermore, the numbers as presented as total visible lesion do not add up. Please clarify

Reviewer \#2: The manuscript addresses a current topic as self collection is an important way to increase screening coverage if HPV testing is available in a low resource setting . Overall the manuscript was well written and worthy of publication. Some minor comments noted:

Introduction should reference that self collections was previously found to be acceptable to women in Botswana (ex reference previous studies on acceptability). .

Page 9 Methods: last paragraph beginning with \"The outcome of VAT\...\....HPV16+ ELSE, HPV negative\...\.....\".

Does ELSE imply versus: please clarify

Page 12 Results section: paragraph following Table 2 that begins with \"Interestingly, the hrHPV prevalence differed between\...\...\"

This was difficult to follow since \# clinic vs \# community referrals were not identified for any of the clinics (A,B, C, D, or E). Therefore it was difficult to assess the prevalence data given, without knowing n values.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229086.r002

Author response to Decision Letter 0

28 Jan 2020

Reviewers\' comments:

Reviewer\'s Responses to Questions

Comments to the Author

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Thank you very much for the insightful and useful feedback to help make this a stronger manuscript. Please see below my responses.

Reviewer \#1: This research article on hrHPV prevalence among HIV negative and WLWH in Botswana based on self-collected sample is a pilot demonstration study that documents success of self-collection in the Botswana context and provides new and insightful data on association of hrHPV and HIV. This is an impactful study and significant to the field of HIV/HPV and advances science on the use of HPV based screening in limited resource setting both among HIV negative and WLWH.

1\. Methods (population)- Recruitment at various facility based on site (health facility vs. community) is difficult to follow based on text presented. It is unclear if two of the recruitment sites only had community health based outreach recruitment?

Thank you for pointing that out. I hope the following is clearer.

All five health facilities conducted recruitment at their respective facilities, while two health facilities (B and E) also conducted recruitment in the community during health outreach activities. In these two facilities, recruitment was planned to be half and half from the health facility and in the community each serves through existing integrated community health outreaches, but 70% were recruited by community outreach for one facility (B).

2\. Result (Table 4)- Data as presented in the text does not match table 4. Furthermore, the numbers as presented as total visible lesion do not add up. Please clarify

Thank you very much for catching that. The text was correct. It has been reviewed and corrected in the table, which is now Table 5, since we added tables to capture 'data not shown'.

Reviewer \#2: The manuscript addresses a current topic as self collection is an important way to increase screening coverage if HPV testing is available in a low resource setting . Overall the manuscript was well written and worthy of publication. Some minor comments noted:

Introduction should reference that self collections was previously found to be acceptable to women in Botswana (ex reference previous studies on acceptability).

This is an excellent point regarding acceptability of self-collection, in other settings. At the time of our study, however, data on acceptability in Botswana was not available. However, our study did collect that information and we are in the process of writing a separate paper on the feasibility and acceptability aspects of the study.

Page 9 Methods: last paragraph beginning with \"The outcome of VAT\...\....HPV16+ ELSE, HPV negative\...\.....\".

Does ELSE imply versus: please clarify

Agree -- versus is more clear and this has been changed.

Page 12 Results section: paragraph following Table 2 that begins with \"Interestingly, the hrHPV prevalence differed between\...\...\"

This was difficult to follow since \# clinic vs \# community referrals were not identified for any of the clinics (A,B, C, D, or E). Therefore it was difficult to assess the prevalence data given, without knowing n values.

This was addressed through the above comment, and copied again below.

All five health facilities conducted recruitment at their respective facilities, while two health facilities (B and E) also conducted recruitment in the community during health outreach activities. In these two facilities, recruitment was planned to be half and half from the health facility and in the community each serves through existing integrated community health outreaches, but 70% were recruited by community outreach for one facility (B).

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

6\. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer \#1: No

Reviewer \#2: No

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.

10.1371/journal.pone.0229086.r003

Decision Letter 1

Chuang

Linus

Academic Editor

© 2020 Linus Chuang

2020

Linus Chuang

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

30 Jan 2020

High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana

PONE-D-19-35746R1

Dear Dr. Varallo,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Linus Chuang

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

10.1371/journal.pone.0229086.r004

Acceptance letter

Chuang

Linus

Academic Editor

© 2020 Linus Chuang

2020

Linus Chuang

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

7 Feb 2020

PONE-D-19-35746R1

High-risk human papillomavirus prevalence in self-collected cervicovaginal specimens from human immunodeficiency virus (HIV)-negative women and women living with HIV living in Botswana

Dear Dr. Varallo:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Linus Chuang

Academic Editor

PLOS ONE

[^1]: **Competing Interests:**Philip E. Castle has received discounted or free HPV tests and assays for research purposes from Roche, Bectin Dickinson, Cepheid, and Arbor Vita Corporation. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
